Charles Schwab’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.5M | Buy |
965,066
+104,298
| +12% | +$1.46M | ﹤0.01% | 1863 |
|
|
2025
Q1 | $13.5M | Sell |
860,768
-18,036
| -2% | -$282K | ﹤0.01% | 1820 |
|
|
2024
Q4 | $12.2M | Buy |
878,804
+18,958
| +2% | +$264K | ﹤0.01% | 1927 |
|
|
2024
Q3 | $8M | Buy |
859,846
+8,522
| +1% | +$79.3K | ﹤0.01% | 2142 |
|
|
2024
Q2 | $7.92M | Buy |
851,324
+100,600
| +13% | +$936K | ﹤0.01% | 2152 |
|
|
2024
Q1 | $7.44M | Buy |
750,724
+179,406
| +31% | +$1.78M | ﹤0.01% | 2132 |
|
|
2023
Q4 | $1.85M | Buy |
571,318
+187,505
| +49% | +$606K | ﹤0.01% | 2644 |
|
|
2023
Q3 | $2.04M | Buy |
383,813
+53,871
| +16% | +$286K | ﹤0.01% | 2592 |
|
|
2023
Q2 | $3.14M | Buy |
329,942
+27,440
| +9% | +$262K | ﹤0.01% | 2412 |
|
|
2023
Q1 | $3.33M | Buy |
302,502
+774
| +0.3% | +$8.51K | ﹤0.01% | 2371 |
|
|
2022
Q4 | $4.47M | Buy |
301,728
+10,635
| +4% | +$157K | ﹤0.01% | 2271 |
|
|
2022
Q3 | $5.56M | Buy |
291,093
+73,833
| +34% | +$1.41M | ﹤0.01% | 2160 |
|
|
2022
Q2 | $4.63M | Buy |
217,260
+16,296
| +8% | +$347K | ﹤0.01% | 2215 |
|
|
2022
Q1 | $3.87M | Buy |
200,964
+2,511
| +1% | +$48.4K | ﹤0.01% | 2394 |
|
|
2021
Q4 | $4.12M | Buy |
198,453
+2,616
| +1% | +$54.3K | ﹤0.01% | 2444 |
|
|
2021
Q3 | $4.68M | Buy |
195,837
+2,455
| +1% | +$58.7K | ﹤0.01% | 2409 |
|
|
2021
Q2 | $5.28M | Buy |
193,382
+13,702
| +8% | +$374K | ﹤0.01% | 2323 |
|
|
2021
Q1 | $5.2M | Buy |
179,680
+38,241
| +27% | +$1.11M | ﹤0.01% | 2283 |
|
|
2020
Q4 | $3.98M | Buy |
141,439
+30,816
| +28% | +$867K | ﹤0.01% | 2332 |
|
|
2020
Q3 | $3.24M | Buy |
110,623
+42,377
| +62% | +$1.24M | ﹤0.01% | 2295 |
|
|
2020
Q2 | $2.06M | Buy |
68,246
+46,225
| +210% | +$1.4M | ﹤0.01% | 2414 |
|
|
2020
Q1 | $657K | Buy |
+22,021
| New | +$657K | ﹤0.01% | 2613 |
|